AstraZeneca has been touting its pipeline full of promising products as a reason it will return to growth by 2017 and has no need to hook up with Pfizer. As if to put an exclamation point on that declaration, the company says it will kick off a U.S. expansion that will add 300 jobs so it can realize that potential.
Merck may soon be the next Big Pharma to step into the Ebola vaccine arena.
With drugs like Yervoy and Sprycel leading its comeback and a pipeline filling up with more biologics, Bristol-Myers Squibb needs someplace to make them, and Ireland will get the prize--an investment of nearly $1 billion and the 400 jobs that will come with it.
India's Cadila Pharmaceuticals has run afoul of the FDA for not doing enough to track down the source of impurities in some products and failing to investigate when customers complained about odors emanating from its APIs.
Actavis nabbed a big portfolio of branded products when it bought Forest Laboratories earlier this year. But it also inherited a quality-control problem.
It has been a tale of two cities when it comes to Eli Lilly's operations in Puerto Rico. Its plant in Carolina has been slotted for $240 million in investments in the last year, benefiting from its buildup in insulin products, and its plant in Guayama is getting axed, a victim of patent losses.
Hospira, the country's largest producer of sterile drugs, is recalling two dozen lots of saline solution, along with 30 lots of other products, because the bags on one of its delivery systems can leak and products might get contaminated.
Novartis is reportedly caught between EU sanctions on Russia and the dictates of Russian President Vladimir Putin, who has told Western drugmakers that he expects them to build plants and transfer technology as the price of admission to the growing market.
Ceva Santé Animale, a global veterinary health group, recently inaugurated its €18 million ($23 million) renovation and extension of its sterile products plant, which will increase injectable drug production capacity.
Roche's Genentech unit is getting some high-profile blowback from a change to its distribution model on three top cancer meds. Hospital and pharmacy executives claim the new regime--which restricts Avastin, Rituxan and Herceptin to a half-dozen specialty distributors--will cost them big money.